The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor
- 1 June 2020
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 86, 102000
Abstract
No abstract availableKeywords
Funding Information
- Vall d́Hebron Institute of Oncology
This publication has 73 references indexed in Scilit:
- Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant CancerCancer Discovery, 2013
- Directional protein secretion by the retinal pigment epithelium: roles in retinal health and the development of age‐related macular degenerationJournal of Cellular and Molecular Medicine, 2013
- Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of CancerScience Translational Medicine, 2013
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialThe Lancet Oncology, 2012
- FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated MechanismsPLOS ONE, 2012
- Fibroblast growth factor signalling: from development to cancerNature Reviews Cancer, 2010
- Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid TumorsClinical Cancer Research, 2010
- FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder TumoursEuropean Urology, 2009
- Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical OutcomeJournal of Clinical Oncology, 2003
- Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked HypophosphatemiaNew England Journal of Medicine, 2003